US · Healthcare · Biotechnology
EPS came in at -0.28 against a street estimate of -0.26 — a miss of 7.7%.
Analysts rate Summit Therapeutics PLC a buy (11 buy, 6 hold, 0 sell out of 17) with an average price target of $30.29.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 4.11% |
| FMR Inc | 1.26% |
| State Street Corp | 1.20% |
| BlackRock Inc | 1.19% |
| Vanguard Capital Management, LLC | 0.72% |
| UBS Group AG | 0.66% |
| Vanguard Portfolio Management, LLC | 0.63% |
| The Goldman Sachs Group Inc | 0.57% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Summit Therapeutics reported a net loss of $208,385 for the quarter ended September 30, 2026, compared with $231,793 in the same p | 2026-11-04 |
| Company announcement · Q4 2026 OTHER NOTABLE POINTS • On November 4, 2026, Summit Therapeutics filed a prospectus supplement to its automatic shelf registration statement on Form S | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • AstraZeneca completed a $2.0 billion strategic equity investment in Summit on October 5, 2026. The investment represents a common | 2026-11-04 |
| Proxy statement · Q4 2026 EXECUTIVE PAY • CEO total compensation and change: The provided proxy excerpt does not disclose executive compensation or state the CEO’s total compe | 2026-10-19 |
| Material agreement · Q3 2026 HEADLINE NUMBERS • Summit Therapeutics agreed to raise $2.0 billion in gross proceeds from AstraZeneca Holdings B.V., an AstraZeneca plc subsidiary. | 2026-09-29 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Summit Therapeutics Inc. (Nasdaq: SMMT) • Headquarters: 601 Brickell Key Dri | 2026-09-15 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Summit Therapeutics Inc. (NASDAQ: SMMT) • Filing Date: September 13, 2026 • | 2026-09-14 |
| Company announcement · Q3 2026 SUMMIT THERAPEUTICS INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • No financial metrics provided in this filing — this is a current report on a clinical | 2026-09-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Expansion of clinical development program for ivonescimab into urothelial carcinoma Summit Therapeutics announced expansion of its clinical development program for ivonescimab, a cancer drug candidate, into a new indication: bladder cancer (urothelial carcinoma). The compan | 2026-08-05 |
| Clinical trial collaboration with GSK to evaluate ivonescimab combination Summit Therapeutics announced three significant developments on January 12, 2026. First, the company reported preliminary cash and short-term investments of approximately $710 million as of | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Summit Therapeutics PLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.